On 29 September 2026, LVJI TECH (01745.HK) said Lu Jia Technology bought 1m shares for HKD 2.93m, lifting the controlling shareholder's stake to 35.08%.
On 29 September 2026, BAIGE DIGITAL (02672.HK) said its board approved converting 169.66m domestic shares into H shares, 52.91% of its issued share capital.
On 29 Sept 2026, NUOBIKAN (02635.HK) agreed to place 16.49m new H shares at HK$8.19, a 13.61% discount, raising net proceeds of ~HK$131.5m.
On 28 Sept 2026, HSBC HOLDINGS (00005.HK) completed its ~US$1bn buy-back after repurchasing 911,200 shares; 48,657,102 shares bought back since 5 August.
On 28 Sept 2026, AEON STORES (00984.HK) further delayed to 7 Oct the circular for the very substantial acquisition of a new lease; it was due by 28 September.
On 29 Sept 2026, LOTUS HORIZON (06063.HK) despatched the composite document for its mandatory unconditional cash offer; acceptance closes 4 p.m. on 20 October.
On 28 Sept 2026, GAC GROUP (02238.HK) said it will buy 50% of FAW Toyota via a share issue; A-share trading resumes on 29 September after a halt since 14 Sept.
On 28 September 2026, SDMC (00901.HK) filed with the CSRC for the H Share Full Circulation to convert 135,755 Unlisted Shares into H Shares one-for-one.
On 28 September 2026, HATCHER GROUP (08365.HK) agreed to buy 51% of Advanced Meditech Force (HK) Ltd., a cancer screening centre and digital pathology firm.
On 28 September 2026, PW MEDTECH (01358.HK) said creditors of its unit Xuzhou Yijia approved an asset sale plan; its Jiangsu plant goes to online auction.
On 28 September 2026, E-HOUSE ENT (02048.HK) said its HK Scheme became effective after the High Court sanctioned it; Cayman Scheme hearing set for 9 October.
On 28 September 2026, DA MING INT'L (01090.HK) said its unit must pay EUR 6,471,425.17 under a Finnish arbitration award, plus EUR 1,323,005.99 in interest.
On 28 September 2026, MSCTECH (01632.HK) engaged Acclime Corporate Advisory as independent investigator; trading has been suspended since 2 July 2026.
On 28 September 2026, REGENT PACIFIC (00575.HK) said its unit Deep Longevity will launch Accrua, a consumer digital health platform, in the US in October 2026.
On 28 September 2026, ROBOSENSE (02498.HK) said Zhu Xiaorui resigned as a NED and audit and remuneration committee member, with Yao Haibo taking those roles.
On 28 September 2026, CSPC PHARMA (01093.HK) said SYS6077 injection has received NMPA approval for clinical trials in China for advanced malignant tumors.
